| http://www.w3.org/ns/prov#value | - In preclinical studies, KP415 exhibited superior pharmacological characteristics that may suggest an improved stimulant-associated side effect profile compared to currently marketed methylphenidate products, potentially reducing symptoms such as loss of appetite and insomnia.
|
